Biogen leadership has said that as part of the research overhaul there will be greater investment in the areas of immunology neuropsychiatry and rare disease. To that end in July the company announced the biggest deal in its history by unadjusted dollar terms a planned 73 billion acquisition of rare disease drugmaker Reata Pharmaceuticals 